DMRADamora Therapeutics, Inc.
Price
+636%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth steady, the market undecided.
We are a biopharmaceutical company developing therapies for the treatment of hematologic disorders. In our previously announced Asset Acquisition (as defined below), we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms (“MPNs”), a group of related, chronic disorders of the bone marrow. Our lead product candidate, DMR-001, targets mutant forms of the calcium binding protein calreticulin (“CALR”), which are collectively known as mutCALR.
In the company’s own words · 10-K filed Mar 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Damora Therapeutics, Inc. (DMRA) reported revenue of $4.1M in Q2 2026 (quarter ended Jun 30, 2026), up 8018% from the same quarter a year earlier. That came with net loss of $31M. For the full year FY2025, revenue was $1.2M (+38% year on year) and net income −$210M.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 20, 2026On July 16, 2026, Damora Therapeutics, Inc., a Cayman Islands exempted company (the “Company”), entered into indemnification agreements with each of its directors and executive officers (collectively, the “Indemnitees” and, the “Indemnification Agreements”), which replaced and superseded any previous indemnification …Material agreement entered · Form 8-K
- May 4, 2026Departure of Chief Financial Officer On April 28, 2026, the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.Director or officer change · Form 8-K
- Apr 20, 2026Dismissal of Independent Registered Public Accounting Firm On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s …Auditor change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.